StockData
Aktis Oncology, Inc. logo

Aktis Oncology, Inc. (AKTS) stock

AKTSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026
$16.15−0.25 (-1.52%)

Close on Nov 20, 2026Market cap $898.26MP/E –Yield –

Aktis Oncology free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026-$26.82M–
Q2 FY2026Jun 30, 2026-$21.85M–
Q1 FY2026Mar 31, 2026-$26.10M–
Q3 FY2025Sep 30, 2025-$17.23M–
Q2 FY2025Jun 30, 2025-$17.72M–
Q1 FY2025Mar 31, 2025-$19.38M–

More Aktis Oncology figures

See a number that looks wrong?